FDA EUA opens doors unapproved COVID-19 treatments


The U.S. Food and Drug Administration (FDA) has opened a wide door of possibilities for the unapproved treatments for the Coronavirus disease (COVID-19). The treatment, though unapproved, has to be a potential one.

The FDA issued an emergency use authorization (EUA) earlier this week demanding the US Biomedical Advanced Research and Development Authority (BARDA) to distribute the donated hydroxychloroquine sulfate and chloroquine phosphate products to doctors when clinical trials don't seem to work on the teen and adult COVID-19 patients.